Alzheimer's disease : recent findings in pathophysiology, diagnostic and therapeutic modalities / edited by Thimmaiah Govindaraju. [print]
Material type:
TextPublication details: Cambridge, UK : Royal Society of Chemistry, (c)2022.Content type: - text
- unmediated
- volume
- 9781839162732
- 1839162732
- RC523.A478..A494 2022
- COPYRIGHT NOT covered - Click this link to request copyright permission: https://lib.ciu.edu/copyright-request-form
| Item type | Current library | Call number | Status | Date due | Barcode | |
|---|---|---|---|---|---|---|
| Circulating Book (checkout times vary with patron status) | G. Allen Fleece Library Nursing - beside IT Help desk on first floor | RC523.A478..A494 2022 (Browse shelf(Opens below)) | Available | 31923002083018 |
Includes bibliographies and index.
Chapter 1 Alzheimer's is a Multifactorial Disease -- 1.1 Introduction -- 1.2 Pathological Events -- 1.3 Biomarkers and Diagnosis -- 1.4 Therapy -- 1.5 Conclusion -- References --
Chapter 2 The Genetic and Biochemical Basis of Alzheimer's Disease -- 2.1 Alzheimer's Disease: A Malady Rooted in Genetics and Pathophysiology -- 2.2 Molecular Basis of AD: Seeing AD at the Level of Molecular Interactions -- 2.3 Amyloid Plaques: A Sticky Substance That Affects Brain Function -- 2.4 Genetics as a Promising Tool for Alzheimer's Disease -- References --
Chapter 3 Alzheimer's Disease Pathology: A Tau Perspective -- 3.1 Tau and Alzheimer's Disease -- 3.2 Conclusions -- 3.3 Future Perspectives for Small Molecules as Tau Therapeutics -- References --
Chapter 4 Structural Insights Into the Amyloidogenic AB and Tau Species in Alzheimer's disease Pathophysiology: Defining Functional Motifs for Therapeutic Interventions -- 4.1 Introduction -- 4.2 Mechanistic Insight Into Amyloidogenesis: Defining the Intermediate Steps -- 4.3 Structural Correlation of AB Pathological Aggregates in AD Etiology -- 4.4 Tau Aggregation and Its Relevance in AD: Insights From NMR Spectroscopy -- 4.5 Conclusion and Future Outlook Acknowledgements -- References --
Chapter 5 Structural Insights on Aggregation Species of AB and Tau, and Their Implications in Alzheimer's Disease -- 5.1 Amyloid Aggregation of AB and Tau in Alzheimer's Disease -- 5.2 Atomic Structures of Tau and AB Fibrils -- 5.3 Fibril Polymorphism and Its Implications in AD Abbreviations -- Acknowledgements -- References --
Chapter 6 Aggregation Species of Amyloid-B and Tau Oligomers in Alzheimer's Disease: Role in Therapeutics and Diagnostics -- 6.1 Introduction -- 6.2 Protein Aggregation Cascades and Various Species of Aggregates -- 6.3 Protein Aggregation Initiation and Underlying Mechanism -- 6.4 Propagation and Seeding Effect of Oligomeric Species -- 6.5 Isolation. Preparation and Characterization of Oligomeric Species -- 6.6 Pathological Aspects of Soluble Oligomers in AD -- 6.7 Oligomers as Therapeutic Targets and Biomarkers -- 6.8 Conclusion -- Abbreviations -- Acknowledgements -- References --
Chapter 7 Role of Metal Ions in Alzheimer's Disease: Mechanistic Aspects Contributing to Neurotoxicity -- 7.1 Introduction -- 7.2 Metal Ions, AB Peptides and Their Interactions -- 7.3 Copper-mediated ROS Production -- 7.4 Modulation of AB Self-assembly by CU and Zn -- 7.5 Metal Targeting Compounds -- 7.6 Concluding Remarks -- Abbreviations -- Acknowledgements -- References --
Chapter 8 Microglial Blockade of the Amyloid Cascade: A New Therapeutic Frontier -- 8.1 Overview - Old and New Positions for Microglia in the Amyloid Cascade -- 8.2 Human Genetic Bases for AD Pathogenesis and Microglial Protection -- 8.3 Microglial TREM2 Activity Opposes the Amyloid Cascade -- 8.4 Therapeutic Strategies to Enhance Microglial Protection in AD -- 8.5 Concluding Remarks -- Author Contributions -- Acknowledgements -- References --
Chapter 9 Post-translational Modifications and Alzheimer's Disease -- 9.1 Introduction -- 9.2 PTMs in AD-- 9.3 Protein Misfolding and Their Aggregation in AD Pathology -- 9.4 Phosphorylation -- 9.5 Glycosylation -- 9.6 Ubiquitination -- 9.7 Sumoylation -- 9.8 Acetylation -- 9.9 Acylation -- 9.10 S-Nitrosylation -- 9.11 Methylation -- 9.12 Solutions and Recommendations to Current Challenges -- 9.13 Conclusion and Future Trends -- Abbreviations -- References --
Chapter 10 Autophagy: Role in Alzheimer's Disease Pathophysiology and Therapeutic Avenues -- 10.1 Introduction -- 10.2 Alzheimer's Disease: Etiological Hypothesis -- 10.3 Autophagy Dysfunction in Neurons During AD - Mechanisms Involved -- 10.4 Autophagy in Glial Cells -- 10.5 AB Degradation and Autophagy -- 10.6 Cross-talk Between Apoptosis and Autophagy -- 10.7 Neuroinflammation and Autophagy -- 10.8 Targeting Autophagy for Therapeutic Strategies -- 10.9 Conclusion and Future Perspectives -- List of Abbreviations -- Conflict of Interest -- Acknowledgements -- References --
Chapter 11 Transmission of Pathogenic Proteins and the Role of Microbial Infection in Alzheimer's Disease Pathology -- 11.1 Introduction -- 11.2 AD Transmission -- 11.3 Role of Microbial Infection in Alzheimer's Disease -- 11.4 Conclusion and Future Outlook -- References --
Chapter 12 The Role of Gut Microbiome in Alzheimer's Disease and Therapeutic Strategies -- 12.1 Introduction -- 12.2 Benefits of Gut Bacteria -- 12.3 Gut Microbiota and Brain Function -- 12.4 Gut Dysbiosis -- 12.5 Therapy -- 12.6 Conclusion and Future Outlook -- References --
Chapter 13 Molecular Probes for the Diagnosis of Alzheimer's Disease with Implications for Multiplexed and Multimodal Strategies -- 13.1 Introduction -- 13.2 AB Biomarkers -- 13.3 Tau as a Biomarker -- 13.4 Neurodegeneration -- 13.5 Indirect Biomarkers -- 13.6 Challenges in AD Diagnosis -- 13.7 Conclusion and Future Outlook -- References --
Chapter 14 Circulating Biomarkers for the Diagnosis of Alzheimer's Disease -- 14.1 Introduction -- 14.2 Core AD Pathology Biomarkers in CSF and Blood -- 14.3 Associated Blood Biomarkers in AD Diagnosis -- 14.4 Non-invasive Sources for Circulating Biomarkers- Saliva, Urine and Tears -- 14.5 Challenges and Prospects for Circulating biomarkers -- 14.6 Conclusion -- References --
Chapter 15 Lactoferrin: A Potential Theragnostic Candidate for Alzheimer's Disease -- 15.1 Introduction -- 15.2 Lactoferrin in AD 15.3 Lf: A Promising Circulatory Biomarker -- 15.4 Lf: A Multifunctional Therapeutic Candidate -- 15.5 Conclusion and Outlook -- References --
Chapter 16 Multifunctional Inhibitors of Multifaceted AB Toxicity of Alzheimer's Disease -- 16.1 Introduction 16.2 Targeting Individual Routed of Amyloid Pathology -- 16.3 Targeting Multiple Toxicities of AD Pathology -- 16.4 Theragnostic Probes -- 16.5 Conclusion and Future Directions -- References --
Chapter 17 Tau-targeting Therapeutic Strategies for Alzheimer's Disease -- 17.1 Introduction -- 17.2 Strategies to Target Tau Pathology -- 17.3 Modulators of PTMs -- 17.4 Tau Aggregation Inhibitors -- 17.5 Microtubule Stabilizers -- 17.6 Immunotherapy -- 17.7 Gene Therapy -- 17.8 Conclusions and Future Directions -- Acknowledgements -- References --
Chapter 18 Computational Development of Alzheimer's Therapeutics and Diagnostics -- 18.1 Introduction -- 18.2 AD Associated Drug Targets and Biomarkers -- 18.3 Molecular Mechanism of Amyloid Plaque -- 18.4 Molecular Mechanism of the Formation of Paired Helical Filaments of Tau Protein -- 18.5 Computational Approaches for Developing -- 18.6 Computational Design of Novel Therapeutics Against Drug Targets in AD -- 18.7 Computational Investigation of Off-target Binding of Diagnostic Agents -- 18.8 Design of Dual Targeting and Multifunctional Ligands -- 18.9 Design of PET Tracers for AD -- 18.10 Design of Optical Probes for Amyloid Imaging -- 18.11 Outlook and Conclusions -- Acknowledgements -- References --
Chapter 19 Targeted Protein Degradation as a Therapeutic Avenue for Alzheimer's Disease -- 19.1 Introduction -- 19.2 Targeted Protein Degradation (TPD) -- 19.3 Alzheimer's Disease (AD) -- 19.4 Mimic of x-Secretase -- 19.5 Miniature Artificial Protease (mAP) -- 19.6 Conclusions and Future Directions -- References --
Chapter 20 Cell-based Therapy for Alzheimer's Disease -- 20.1 Cell-based Therapy -- 20.2 Stem Cell Treatments for AD -- References --
Chapter 21 Experimental Models to Study Alzheimer's Disease -- 21.1 In Vivo Models -- 21.2 In Vitro AD Models -- 21.3 Conclusion -- Acknowledgements -- References --
Chapter 22 Ethnic and Racial Differences in The Pathophysiology of Alzheimer's Disease -- 22.1 Introduction -- 22.2 Cross-comparison of Racial and Ethnic Disparities -- 22.3 Reasons for Ethnic and Racial Disparities -- 22.4 Impact of Ethno-racial Aspects on Diagnostic Techniques -- 22.5 Genetic Risk for Alzheimer's Disease: Epidemiological Comparison -- 22.6 Non- genetic Risk for Alzheimer's Disease: Epidemiological Comparison -- 22.7 Participation of Cohort Groups in Clinical Trails, Respective Outcomes and Medication -- 22.8 Neuropsychiatric Symptoms of AD in Ethno-racial Groups -- 22.9 Impact of Ethno-racial Factors in the Pathogenesis of Alzheimer's Disease -- 22.10 Interferences to Lessen the Racial and Ethnic Disparities -- 22.11 Conclusion and Future Perspective -- Acknowledgments -- References --
Subject Index.
"Alzheimer's Disease: Recent Findings in Pathophysiology, Diagnostic and Therapeutic Modalities provides a comprehensive overview from aetiology and neurochemistry to diagnosis, evaluation and management of Alzheimer's disease, and latest therapeutic approaches. Intended to provide an introduction to all aspects of the disease and latest developments, this book is ideal for students, postgraduates and researchers in neurochemistry, neurological drug discovery and Alzheimer's disease." AMAZON
COPYRIGHT NOT covered - Click this link to request copyright permission:
https://lib.ciu.edu/copyright-request-form
Print version record.
There are no comments on this title.